cleaving CCL11, which decreases eosinophil recruitment.

Finally, the authors showed that CCL11 production by tumours can be induced by the alarmin IL-33. High levels of IL-33 were detected in the HCC and breast cancer cell lines, and intratumoural administration of IL-33 in vivo induced CCL11 expression. Antibody-mediated blockade of IL-33 or deficiency of the IL-33 receptor prevented the tumour-inhibitory effect of DPP4i.

This study identifies an IL-33–CCL11–eosinophil antitumour axis that could be enhanced in certain tumour models through targeting DPP4 enzymatic activity. Importantly, the addition of DPP4i increased the response to checkpoint blockade therapy in the mouse models, which opens up the possibility of combination therapies.

Kirsty Minton

ORIGINAL ARTICLE Hollande, C. et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. *Nat. Immunol.* **20**, 257–264 (2019)

independent of CD8⁺ T cell activity. Finally, in a cohort of patients with PDA who had surgery followed by adjuvant gemcitabine, better survival was seen in individuals with low macrophage burdens in tumours. A caveat here is that patients with high macrophage burdens also fare worse in the absence of gemcitabine therapy, most likely reflecting other detrimental activities of macrophages in the tumour microenvironment.

As well as identifying a potential way in which to improve the clinical efficacy of gemcitabine, these findings are interesting in that they suggest alternatively activated macrophages synthesize and transfer pyrimidines to other cells. Pyrimidine salvage was previously reported to be important for lymphocyte development, and it will be interesting to explore its contribution to other physiological responses.

Yvonne Bordon

ORIGINAL ARTICLE Halbrook, C. J. et al. Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. *Cell Metab.* <https://doi.org/10.1016/j.cmet.2019.02.001> (2019)

MUCOSAL IMMUNOLOGY

Microbiota supports air attack

A large body of work has helped to define the immunological effects of tissue-associated microbiota, particularly in the intestine, but relatively little is known concerning the lung microbiota. Reporting in *Immunity*, Yang et al. show that dysregulation of the lung microbiota in a mouse model drives pulmonary fibrosis by inducing the upregulation of IL-17B. They propose that dysregulation of the pulmonary microbiota could lie at the heart of idiopathic pulmonary fibrosis (IPF), a severe lung disease of unknown aetiology.

Historically, the lower respiratory tract was considered to be sterile. However, recent studies identified a lung microbiome and there are reports that this is altered in patients with IPF. The authors used a mouse model of bleomycin-induced fibrosis to explore the effects of the microbiota in fibrotic lung disease. Bleomycin treatment induced ~50% mortality in wild-type mice and this was associated with peribronchial immune cell infiltration and pulmonary fibrosis. Antibiotic-mediated depletion of lung bacteria led to reduced immune cell infiltration and fibrosis in response to bleomycin and protected against death. By contrast, depletion of fungi had no effect on bleomycin-induced pathology. Oral delivery of antibiotics to restrict microbiota depletion to the gut also did not protect mice in the bleomycin model. Therefore, the lung-resident microbiota seems to be a key driver of fibrotic disease in this mouse model.

Antibiotic treatment before bleomycin administration was associated with reduced expression of IL-17 family cytokines, which have previously been linked to lung fibrosis. Deficiency of IL-17A, IL-17B or IL-17E alleviated bleomycin-induced fibrosis but these protective effects were lost if mice were treated with antibiotics targeting the lung microbiota. Therefore, induction of IL-17 family members by the lung microbiota is crucial for bleomycin-induced fibrotic disease.

As IL-17B has been less well-studied in the context of fibrosis, the authors subsequently focused on this cytokine. They used an adenoviral system to express IL-17B in lungs and found that this induced the expression of pro-inflammatory and pro-fibrotic genes. Further experiments showed that IL-17B signals through an IL-17RB–IL-17RA heterodimeric receptor complex and that IL-17RB expression on stromal cells and epithelial cells, but not on bone marrow-derived cells, was necessary for bleomycin-induced lung fibrosis. Stimulation of primary mouse type II epithelial cells or cells from a human lung epithelial cell-line with IL-17B induced expression of pro-inflammatory cytokines, and IL-17B was shown to synergize with tumour necrosis factor

Credit: S. Bradbrook/
Springer Nature Limited

(TNF) to further promote expression of pro-inflammatory and pro-fibrotic genes in lung epithelial cells. Accordingly, in the lungs of bleomycin-treated IL-17B-deficient mice, there was decreased expression of pro-inflammatory and pro-fibrotic genes associated with T helper 17 (T_H17) cell-type immune responses, as well as an overall reduction in neutrophils and T_H17 cells.

The authors next examined the microbiota components linked to fibrosis. They intranasally inoculated microbiota-depleted mice with different bacterial species before bleomycin challenge and identified three *Bacteroidetes* species — *Bacteroides ovatus*, *Bacteroides stercoris* and *Prevotella melaninogenica* — that markedly increased lung fibrosis and mouse mortality. All of these species were expanded in the lungs of wild-type mice following bleomycin treatment; the authors linked this to an increase in host metabolites that support bacterial growth in the bleomycin-damaged lung. The three *Bacteroidetes* species did not induce expression of IL-17 family cytokines in the lungs of resting mice but were found to induce IL-17B and IL-17A following bleomycin treatment.

Interestingly, the authors found that outer membrane vesicles (OMVs) produced by *B. stercoris* and *P. melaninogenica* induced expression of IL-17B and IL-17A in the lungs. These bacterial OMVs upregulated IL-17B in macrophages in a process dependent on Toll-like receptor 4 (TLR4), TLR2 and MYD88, and IL-17B induction by OMVs was reduced if lipopolysaccharide was neutralized.

Therefore, bleomycin-induced lung damage can support the expansion of *Bacteroidetes* species that promote fibrotic responses by producing OMVs that induce IL-17B production in macrophages. Similar dysregulation of the lung microbiota may contribute to pulmonary fibrosis in humans, and the authors suggest that antibiotics or targeting IL-17B could be useful in treating IPF and other fibrotic diseases.

Yvonne Bordon

ORIGINAL ARTICLE Yang, D. et al. Dysregulated lung commensal bacteria drive interleukin-17B production to promote pulmonary fibrosis through their outer membrane vesicles. *Immunity* <https://doi.org/10.1016/j.immuni.2019.02.001> (2019)